Trial Profile

A Phase 1, Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Pharmacokinetics of ORIC-114 Tablet Formulation in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ORIC 114 (Primary)
Indications HER2 positive breast cancer; Non-small cell lung cancer; Solid tumours
Focus Pharmacokinetics
Sponsors ORIC Pharmaceuticals

Most Recent Events

25 Feb 2025 According to a ORIC Pharmaceuticals media release, ORIC-114 data as a monotherapy in 1L EGFR atypical mutations are expected in mid-2026.
17 Jan 2024 Status changed from recruiting to completed.
30 Oct 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com